Latest news with #Lennox–Gastautsyndrome
Globe and Mail
04-04-2025
- Health
- Globe and Mail
Lennox-Gastaut syndrome Market to Expand Significantly by 2034, States DelveInsight Report
The Lennox–Gastaut syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lennox–Gastaut syndrome pipeline products will significantly revolutionize the Lennox–Gastaut syndrome market dynamics. DelveInsight's 'Lennox–Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Lennox–Gastaut syndrome, historical and forecasted epidemiology as well as the Lennox–Gastaut syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Lennox–Gastaut syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. To Know in detail about the Lennox–Gastaut syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lennox–Gastaut syndrome Market Forecast Some of the key facts of the Lennox–Gastaut syndrome Market Report: The Lennox–Gastaut syndrome market size was valued ~596 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In June 2024, UCB, a global biopharmaceutical company, announced that Epilepsia published results from a comprehensive scoping review evaluating the effectiveness of FINTEPLA® (fenfluramine) in reducing the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) in patients with developmental and epileptic encephalopathies (DEEs). The review demonstrated a significant reduction in both GTCS and TCS across various DEEs, further supporting the data from the FINTEPLA clinical trial program. FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged two years and older. In June 2024, Takeda (TSE:4502/NYSE:TAK) has announced topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 trial that assessed soticlestat (TAK-935) in combination with standard care versus placebo plus standard care in patients with refractory Dravet syndrome (DS). While soticlestat did not meet the primary endpoint of reducing convulsive seizure frequency compared to placebo (p-value = 0.06), it showed clinically meaningful and nominally significant results in six key secondary endpoints, including responder rates, caregiver and clinician global impressions of improvement, and seizure intensity and duration scales during the 16-week treatment period (all p-values ≤ 0.008). DelveInsight's analysis forecasts that the Lennox-Gastaut Syndrome market will expand at a CAGR of 4.5% from 2024 to 2034. According to DelveInsight's epidemiology model, there were approximately 115,000 prevalent cases of Lennox-Gastaut Syndrome in the 7MM in 2023. This figure is expected to increase over the forecast period (2024-2034), largely due to heightened awareness and advancements in diagnostic methods. In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome across the 7MM totaled approximately 81,000. This number is expected to increase throughout the forecast period. In 2023, the United States recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 34,000 cases, a figure projected to rise throughout the forecast period. In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome in the US were distributed by gender, with males representing about 25,000 cases and females accounting for approximately 9,000 cases. In 2023, among the EU4 and the UK, Germany recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with roughly 11,000 cases. France followed with approximately 9,600 cases, and Italy had around 8,800 cases. In 2023, Japan had the fewest diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 3,000 cases. Key Lennox–Gastaut syndrome Companies: Takeda /Ovid, SK Life Science, Inc., Epygenix, CuroNZ Ltd, Eisai, and others Key Lennox–Gastaut syndrome Therapies: Soticlestat, Carisbamate, EPX-100, NRP2945, Fycompa, TAK-935/OV935 (Soticlestat), and others The Lennox–Gastaut syndrome epidemiology based on gender analyzed that Lennox–Gastaut syndrome is found to be more prevalent in males than in females, for some undefined reason, with the male to female ratio being 1:6 (relative risk, 5.31). Lennox–Gastaut syndrome Overview Lennox-Gastaut syndrome (LGS) is a rare and severe form of epilepsy that typically begins in early childhood, often between ages 3 and 5. It is characterized by multiple types of seizures, including tonic (stiffening) and atonic (loss of muscle tone) seizures. People with LGS also experience developmental delays, cognitive impairments, and behavioral issues. The causes of LGS can vary, including genetic factors, brain injury, or other underlying conditions. Treatment usually involves a combination of medications, and in some cases, surgery or dietary therapies, to manage the seizures and improve quality of life. Get a Free sample for the Lennox–Gastaut syndrome Market Report - Lennox–Gastaut syndrome Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Lennox–Gastaut syndrome Epidemiology Segmentation: The Lennox–Gastaut syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Lennox–Gastaut syndrome in the 7MM Total Diagnosed Prevalent Cases of Lennox–Gastaut syndrome in the 7MM Gender-specific Diagnosed Prevalent Cases of Lennox–Gastaut syndrome in the 7MM Seizures-specific Diagnosed Prevalent Cases of Lennox Gastaut syndrome in the 7MM Download the report to understand which factors are driving Lennox–Gastaut syndrome epidemiology trends @ Lennox–Gastaut syndrome Epidemiological Insights Lennox–Gastaut syndrome Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lennox–Gastaut syndrome market or expected to get launched during the study period. The analysis covers Lennox–Gastaut syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Lennox–Gastaut syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Lennox–Gastaut syndrome Therapies and Key Companies To know more about Lennox–Gastaut syndrome treatment, visit @ Lennox–Gastaut syndrome Medications Lennox–Gastaut syndrome Market Strengths The use of off-label branded and generic prescription medications targeted at individual symptoms of LennoxGastaut syndrome (LGS) Lennox–Gastaut syndrome Market Opportunities New therapeutic options are needed to address the unmet need for effective and curative therapies for Lennox-Gastaut syndrome (LGS). Scope of the Lennox–Gastaut syndrome Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Lennox–Gastaut syndrome Companies: Takeda /Ovid, SK Life Science, Inc., Epygenix, CuroNZ Ltd, Eisai, Takeda, Ovid, and others Key Lennox–Gastaut syndrome Therapies: Soticlestat, Carisbamate, EPX-100, NRP2945, Fycompa, TAK-935/OV935 (Soticlestat), and others Lennox–Gastaut syndrome Therapeutic Assessment: Lennox–Gastaut syndrome current marketed and Lennox–Gastaut syndrome emerging therapies Lennox–Gastaut syndrome Market Dynamics: Lennox–Gastaut syndrome market drivers and Lennox–Gastaut syndrome market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Lennox–Gastaut syndrome Unmet Needs, KOL's views, Analyst's views, Lennox–Gastaut syndrome Market Access and Reimbursement Table of Contents 1. Lennox–Gastaut syndrome Market Report Introduction 2. Executive Summary for Lennox–Gastaut syndrome 3. SWOT analysis of Lennox–Gastaut syndrome 4. Lennox–Gastaut syndrome Patient Share (%) Overview at a Glance 5. Lennox–Gastaut syndrome Market Overview at a Glance 6. Lennox–Gastaut syndrome Disease Background and Overview 7. Lennox–Gastaut syndrome Epidemiology and Patient Population 8. Country-Specific Patient Population of Lennox–Gastaut syndrome 9. Lennox–Gastaut syndrome Current Treatment and Medical Practices 10. Lennox–Gastaut syndrome Unmet Needs 11. Lennox–Gastaut syndrome Emerging Therapies 12. Lennox–Gastaut syndrome Market Outlook 13. Country-Wise Lennox–Gastaut syndrome Market Analysis (2020–2034) 14. Lennox–Gastaut syndrome Market Access and Reimbursement of Therapies 15. Lennox–Gastaut syndrome Market Drivers 16. Lennox–Gastaut syndrome Market Barriers 17. Lennox–Gastaut syndrome Appendix 18. Lennox–Gastaut syndrome Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Yahoo
21-02-2025
- Health
- Yahoo
Seven things to know about epilepsy in children as new drug rolled out
Children in England living with a rare and severe form of epilepsy could soon benefit from a new drug being rolled out on the NHS. Fenfluramine has been recommended by the National Institute for Health and Care Excellence (NICE) for patients aged two and over with Lennox–Gastaut syndrome (LGS). LGS is a rare and severe form of epilepsy that starts in early childhood and is resistant to many treatments. It is thought that around 1-2% of the 60,000 children in England with epilepsy have LGS. The drug, the first non-cannabis-based treatment approved for this form of epilepsy, is taken as an oral liquid medicine daily and works by increasing the levels of serotonin in the brain to reduce seizures. Lisa Suchet, whose 10-year-old son has LGS, says the drug offers her son hope of "seizure freedom". "My son has suffered with seizures since he was five weeks of age, including drop seizures, which are the most devastating," she said. "They occur without warning, cause immediate collapse and the risk of head injury is high due to the sudden fall." Suchet says until now there have been so few effective drugs for seizure control. "Many don't work for all patients; many have debilitating side effects or interactions with other meds a patient might have to take," she explains. "That there is another option now available, which has shown effective results and minimal side effects is a huge comfort. It is essentially providing a chance of seizure freedom, which is essentially another chance at life really; for the patient and the family or carers who are impacted so significantly by this awful disease." Epilepsy is a neurological condition (affecting the brain and nervous system) where a person has a tendency to have seizures that start as a disruption of signals in the brain. Some children stop having seizures after a period of being on treatment, others, however, need treatment for long periods. The condition is more common than many people realise, with around one child in every 200 living with epilepsy. The NHS says that while there is sometimes a clear reason for epilepsy developing, for example a severe blow to the head, an infection of the brain such as meningitis, or brain damage due to lack of oxygen during a difficult birth, in other cases it isn't obvious. It's possible a child's epilepsy could be partly caused by their genes affecting how their brain works, as the NHS estimates around one in three people with epilepsy have a family member with it. Seizures are caused by a sudden burst of electrical activity in the brain, which temporarily disrupts the way messages are passed between brain cells. There are a number of different types of epileptic seizure, but the type a child has depends on which part of their brain is affected by the condition. The Epilepsy Society says there are two main types of seizure: focal seizures and generalised seizures. "Focal seizures start in only one side of the brain and generalised seizures affect both sides of the brain," the charity explains. "Generally, adults and children have the same types of seizure. However, some may be more common in childhood (for example, absence seizures which can be very brief and are often mistaken for 'daydreaming' or not paying attention)." The kind of symptoms a child experiences during a seizure can include: jerking of the body repetitive movements unusual sensations such as a strange taste in the mouth or a strange smell, or a rising feeling in the stomach. In some types of seizure, a child may be aware of what is happening. In other types, a child will be unconscious and have no memory of what happened afterwards. Some children may have seizures when they are sleeping (sometimes called "asleep" or 'nocturnal' seizures). The Epilepsy Society says some children's seizures can occur in response to triggers such as stress, excitement, boredom, missed medication, or lack of sleep. The charity recommends keeping a diary of your child's seizures, which can help to see if there are any patterns to when they happen and what may have triggered them. If a child experiences a tonic-clonic seizure (when their body goes stiff and the type of seizures most people associate with epilepsy) the Great Ormond Street Hospital recommends not trying to stop it. "Instead, move any furniture out of the way, try to loosen any tight clothing around the neck and stay with the child until the seizure has finished," the site explains. "As soon as uncontrolled movements finish, lay the child on their side in the recovery position." If a child has another type of seizure, it is recommended you sit them down quietly and stay with them until they are fully recovered and alert. Reassure the child calmly. The NHS recommends calling 999 for an ambulance if your child: is having a seizure for the first time has a seizure that lasts more than 5 minutes has lots of seizures in a row has breathing problems or has seriously injured themselves The number and type of seizures your child is having may change over time. But some children do outgrow their epilepsy by their mid to late teens. According to the Epilepsy Society this is called "spontaneous remission". There is currently no cure for epilepsy, but treatment can help most children with epilepsy have fewer seizures or stop having seizures completely. medicines called anti-epileptic drugs – these are the main treatment surgery to remove a small part of the brain that's causing the seizures a procedure to put a small electrical device inside the body that can help control seizures a special diet (ketogenic diet) that can help control seizures In very rare cases when medication does not help, and scans indicate a structural brain abnormality is the cause, surgery may be suggested. Read more about epilepsy: First UK child to have epilepsy device fitted in his brain has huge reduction in seizures (Independent, 2-min read) I had a seizure minutes before my final exams at uni (Yahoo Life UK, 11-min read) Epilepsy myths debunked as study reveals most Brits still believe misconceptions about the condition (Yahoo Life UK, 3-min read)
Yahoo
20-02-2025
- Health
- Yahoo
Seven things to know about epilepsy in children as new drug rolled out
Children in England living with a rare and severe form of epilepsy could soon benefit from a new drug being rolled out on the NHS. Fenfluramine has been recommended by the National Institute for Health and Care Excellence (NICE) for patients aged two and over with Lennox–Gastaut syndrome (LGS). LGS is a rare and severe form of epilepsy that starts in early childhood and is resistant to many treatments. It is thought that around 1-2% of the 60,000 children in England with epilepsy have LGS. See for yourself — The Yodel is the go-to source for daily news, entertainment and feel-good stories. By signing up, you agree to our Terms and Privacy Policy. The drug, the first non-cannabis-based treatment approved for this form of epilepsy, is taken as an oral liquid medicine daily and works by increasing the levels of serotonin in the brain to reduce seizures. Lisa Suchet, whose 10-year-old son has LGS, says the drug offers her son hope of "seizure freedom". "My son has suffered with seizures since he was five weeks of age, including drop seizures, which are the most devastating," she said. "They occur without warning, cause immediate collapse and the risk of head injury is high due to the sudden fall." Suchet says until now there have been so few effective drugs for seizure control. "Many don't work for all patients; many have debilitating side effects or interactions with other meds a patient might have to take," she explains. "That there is another option now available, which has shown effective results and minimal side effects is a huge comfort. It is essentially providing a chance of seizure freedom, which is essentially another chance at life really; for the patient and the family or carers who are impacted so significantly by this awful disease." Epilepsy is a neurological condition (affecting the brain and nervous system) where a person has a tendency to have seizures that start as a disruption of signals in the brain. Some children stop having seizures after a period of being on treatment, others, however, need treatment for long periods. The condition is more common than many people realise, with around one child in every 200 living with epilepsy. The NHS says that while there is sometimes a clear reason for epilepsy developing, for example a severe blow to the head, an infection of the brain such as meningitis, or brain damage due to lack of oxygen during a difficult birth, in other cases it isn't obvious. It's possible a child's epilepsy could be partly caused by their genes affecting how their brain works, as the NHS estimates around one in three people with epilepsy have a family member with it. Seizures are caused by a sudden burst of electrical activity in the brain, which temporarily disrupts the way messages are passed between brain cells. There are a number of different types of epileptic seizure, but the type a child has depends on which part of their brain is affected by the condition. The Epilepsy Society says there are two main types of seizure: focal seizures and generalised seizures. "Focal seizures start in only one side of the brain and generalised seizures affect both sides of the brain," the charity explains. "Generally, adults and children have the same types of seizure. However, some may be more common in childhood (for example, absence seizures which can be very brief and are often mistaken for 'daydreaming' or not paying attention)." The kind of symptoms a child experiences during a seizure can include: jerking of the body repetitive movements unusual sensations such as a strange taste in the mouth or a strange smell, or a rising feeling in the stomach. In some types of seizure, a child may be aware of what is happening. In other types, a child will be unconscious and have no memory of what happened afterwards. Some children may have seizures when they are sleeping (sometimes called "asleep" or 'nocturnal' seizures). The Epilepsy Society says some children's seizures can occur in response to triggers such as stress, excitement, boredom, missed medication, or lack of sleep. The charity recommends keeping a diary of your child's seizures, which can help to see if there are any patterns to when they happen and what may have triggered them. If a child experiences a tonic-clonic seizure (when their body goes stiff and the type of seizures most people associate with epilepsy) the Great Ormond Street Hospital recommends not trying to stop it. "Instead, move any furniture out of the way, try to loosen any tight clothing around the neck and stay with the child until the seizure has finished," the site explains. "As soon as uncontrolled movements finish, lay the child on their side in the recovery position." If a child has another type of seizure, it is recommended you sit them down quietly and stay with them until they are fully recovered and alert. Reassure the child calmly. The NHS recommends calling 999 for an ambulance if your child: is having a seizure for the first time has a seizure that lasts more than 5 minutes has lots of seizures in a row has breathing problems or has seriously injured themselves The number and type of seizures your child is having may change over time. But some children do outgrow their epilepsy by their mid to late teens. According to the Epilepsy Society this is called "spontaneous remission". There is currently no cure for epilepsy, but treatment can help most children with epilepsy have fewer seizures or stop having seizures completely. medicines called anti-epileptic drugs – these are the main treatment surgery to remove a small part of the brain that's causing the seizures a procedure to put a small electrical device inside the body that can help control seizures a special diet (ketogenic diet) that can help control seizures In very rare cases when medication does not help, and scans indicate a structural brain abnormality is the cause, surgery may be suggested. Read more about epilepsy: First UK child to have epilepsy device fitted in his brain has huge reduction in seizures (Independent, 2-min read) I had a seizure minutes before my final exams at uni (Yahoo Life UK, 11-min read) Epilepsy myths debunked as study reveals most Brits still believe misconceptions about the condition (Yahoo Life UK, 3-min read)
